Keyword: Themis Bioscience

Themis' win comes after the FDA granted the same designation to chikungunya candidates from PaxVax and Valneva.

The FDA fast-tracked Valneva's shot against chikungunya, a disease with no approved vaccines.

There aren’t any vaccines against the painful viral infection chikungunya, but with new phase 2 results, Themis is one step closer to changing that.

Right on the heels of last week's deal in Lassa fever, CEPI has awarded IDT Biologika up to $36 million for MERS research.

Here is some other vaccine news of note for the week.

Merck and international agencies are preparing to roll out the experimental vaccine, hoping to stifle a new wave of cases that has killed 19 people.

PaxVax picked up the FDA's fast track tag for its chikungunya vaccine.

The five-year grant will support Inovio through phase 2 development of DNA vaccines against Lassa fever and MERS.

Experts say technology is advancing to develop vaccines faster at a time of increasing emerging disease outbreaks.

Amid a devastating outbreak in Nigeria, Themis plans to be first to test a Lassa fever vaccine in humans as early as this year.